Strata Critical Medical Projects High-Teens EBITDA Growth Through 2027 and Authorizes $20 Million Share Buyback
Strata Critical Medical (SRTA) reported third-quarter results that exceeded management guidance, driven by increased market share gains and improved cash flow conversion. The company demonstrated strong operational efficiency, highlighting its ability to generate significant liquidity from its core business activities. Looking ahead, the company has issued optimistic long-term guidance, projecting organic adjusted EBITDA growth in the high-teens through 2027. To reward shareholders and signal confidence in its valuation, Strata has authorized a new $20 million share buyback program.
Topics: cash flow earnings beat financial performance market share
Read the full article at Seeking Alpha
Part of the story Strata critical medical signals 2027 high-teens organic adjusted EBITDA growth while authorizing $20M buyback (2 articles)